La Jolla Pharmaceutical Company , a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It engages in developing LJPC-501, a formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension; and LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. The company is also developing LJPC-30S, which is the gentamicin derivative program for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.

  • Independent Director David Ramsay Just Bought A Handful Of Shares In La Jolla Pharmaceutical Company (NASDAQ:LJPC)
    on August 25, 2020 at 12:31 pm

    Potential La Jolla Pharmaceutical Company (NASDAQ:LJPC) shareholders may wish to note that the Independent Director...

  • La Jolla Pharmaceutical (NASDAQ:LJPC) Share Prices Have Dropped 87% In The Last Five Years
    on August 21, 2020 at 6:02 pm

    We're definitely into long term investing, but some companies are simply bad investments over any time frame. It hits...

  • La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate Progress
    on August 6, 2020 at 12:30 pm

    SAN DIEGO, California, Aug. 06, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and six months ended June 30, 2020 and highlighted recent corporate progress.Recent Corporate Progress * Acquisition of Tetraphase Pharmaceuticals, Inc.: On July 28, 2020, La Jolla completed its acquisition of Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company focused on commercializing its novel tetracycline, XERAVA™ (eravacycline), to treat serious and life-threatening infections, for $43 million in upfront cash plus potential future cash payments of up to $16 million. For the three and six months ended June 30, 2020, U.S. net sales of XERAVA, which was launched in October 2018, were $1.5 million and $3.2 million, up 88% and 191%, respectively, from the same periods in 2019. Complete financial results of Tetraphase for the six months ended June 30, 2020 will be included in an amended Form 8-K to be filed by La Jolla on or before October 13, 2020. Financial results for periods ending September 30, 2020 and beyond will include Tetraphase’s financial results subsequent to the acquisition closing date of July 28, 2020.   * Appointment of Larry Edwards as President and Chief Executive Officer: Effective July 28, 2020, La Jolla’s Board of Directors appointed Larry Edwards as President and Chief Executive Officer of La Jolla.“With two, FDA-approved, innovative therapies for life-threatening diseases, La Jolla is well-positioned to help patients in need,” said Larry Edwards, President and Chief Executive Officer of La Jolla. “By leveraging the stronger platform that the combined company will provide, we look forward to increasing patient access to these important medicines.”Financial ResultsFor the three and six months ended June 30, 2020, U.S. net sales of GIAPREZA were $5.8 million and $13.4 million, up 2% and 33%, respectively, from the same periods in 2019.La Jolla’s net loss for the three and six months ended June 30, 2020 was $15.6 million and $24.2 million, or $0.57 and $0.89 per share, respectively, compared to $30.4 million and $62.1 million, or $1.12 per share and $2.29 per share, respectively, for the same periods in 2019.As of June 30, 2020, La Jolla had $71.4 million of cash and short-term investments, compared to $87.8 million as of December 31, 2019. Net cash used in operating activities for the three and six months ended June 30, 2020 was $8.4 million and $20.6 million, respectively, down 49% and 58%, respectively, from the same periods in 2019.About GIAPREZAGIAPREZA™ (angiotensin II) for injection is approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. GIAPREZA is approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. GIAPREZA mimics the body’s endogenous angiotensin II peptide, which is central to the renin-angiotensin-aldosterone system, which in turn regulates blood pressure. Prescribing information for GIAPREZA is available at http://www.giapreza.com. The European Summary of Product Characteristics is available on the EMA website: www.ema.europa.eu/en/medicines/human/EPAR/giapreza. GIAPREZA is marketed in the U.S. by La Jolla Pharmaceutical Company on behalf of La Jolla Pharma, LLC, its wholly owned subsidiary.GIAPREZA Important Safety InformationContraindicationsNone.Warnings and PrecautionsThere is a potential for venous and arterial thrombotic and thromboembolic events in patients who receive GIAPREZA. Use concurrent venous thromboembolism (VTE) prophylaxis.Adverse ReactionsThe most common adverse reactions that were reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events.Drug InteractionsAngiotensin converting enzyme (ACE) inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers (ARBs) may reduce response to GIAPREZA.You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.For additional information, please see Full Prescribing Information for the United States and the Summary of Product Characteristics for the European Union.About XERAVAXERAVA™ (eravacycline) for injection is a novel fluorocycline of the tetracycline class of antibacterials that is approved by the U.S. Food and Drug Administration (FDA) for the treatment of complicated intra‑abdominal infections (cIAI) in patients 18 years of age and older. XERAVA is approved by the European Commission (EC) for the treatment of cIAI in adults. Prescribing information for XERAVA is available at www.xerava.com. XERAVA is marketed in the U.S. by Tetraphase Pharmaceuticals, Inc., a wholly owned subsidiary of La Jolla.XERAVA Important Safety InformationXERAVA is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older.XERAVA is not indicated for the treatment of complicated urinary tract infections.To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.XERAVA is contraindicated for use in patients with known hypersensitivity to eravacycline, tetracycline-class antibacterial drugs or to any of the excipients. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with XERAVA.The use of XERAVA during tooth development (last half of pregnancy, infancy and childhood to the age of eight years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.The use of XERAVA during the second and third trimester of pregnancy, infancy and childhood up to the age of eight years may cause reversible inhibition of bone growth.Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis.The most common adverse reactions observed in clinical trials (incidence ≥ 3%) were infusion site reactions, nausea and vomiting.XERAVA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions including photosensitivity, pseudotumor cerebri and anti-anabolic action, which has led to increased blood urea nitrogen, azotemia, acidosis, hyperphosphatemia, pancreatitis and abnormal liver function tests, have been reported for other tetracycline-class antibacterial drugs, and may occur with XERAVA. Discontinue XERAVA if any of these adverse reactions are suspected.You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.For additional information, please see Full Prescribing Information for the United States.About La Jolla Pharmaceutical CompanyLa Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZA™ (angiotensin II) is approved by the U.S. FDA as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAVA™ (eravacycline) is approved by the U.S. FDA for the treatment of complicated intra-abdominal infections. For more information, please visit www.ljpc.com.Forward-looking StatementsThis press release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: GIAPREZA™ (angiotensin II) and XERAVA™ (eravacycline) sales; whether La Jolla will realize the benefits from the acquisition of Tetraphase Pharmaceuticals, Inc.; regulatory actions relating to La Jolla’s products by the U.S. FDA, European Commission and/or other regulatory authorities; cash used in operating activities and our capital requirements; and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. LA JOLLA PHARMACEUTICAL COMPANYCondensed Consolidated Balance Sheets (in thousands, except par value and share amounts) June 30, 2020 December 31, 2019  (Unaudited)   ASSETS    Current assets:    Cash$68,353  $87,820  Short-term investments3,062  —  Accounts receivable, net1,843  2,960  Inventory, net3,120  2,211  Prepaid expenses and other current assets2,792  4,467  Total current assets79,170  97,458  Property and equipment, net12,827  18,389  Right-of-use lease asset14,792  15,491  Restricted cash606  909  Total assets$107,395  $132,247       LIABILITIES AND SHAREHOLDERS’ DEFICIT    Current liabilities:    Accounts payable$2,481  $4,177  Accrued expenses6,772  9,312  Accrued payroll and related expenses5,741  8,332  Lease liability, current portion2,890  2,766  Total current liabilities17,884  24,587  Lease liability, less current portion25,000  26,481  Deferred royalty obligation, net124,406  124,379  Other noncurrent liabilities15,317  12,790  Total liabilities182,607  188,237  Commitments and contingencies (Note 6)    Shareholders’ deficit:    Common Stock, $0.0001 par value; 100,000,000 shares authorized, 27,358,611 and 27,195,469 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively3  3  Series C-12 Convertible Preferred Stock, $0.0001 par value; 11,000 shares authorized, 3,906 shares issued and outstanding at June 30, 2020 and December 31, 2019; and liquidation preference of $3,906 at June 30, 2020 and December 31, 20193,906  3,906  Additional paid-in capital982,393  977,432  Accumulated deficit(1,061,514) (1,037,331) Total shareholders’ deficit(75,212) (55,990) Total liabilities and shareholders’ deficit$107,395  $132,247           LA JOLLA PHARMACEUTICAL COMPANYCondensed Consolidated Statements of Operations (Unaudited) (in thousands, except per share amounts) Three Months Ended June 30, Six Months Ended June 30,  2020 2019 2020 2019 Revenue        Net product sales$5,805  $5,703  $13,396  $10,098  Total revenue5,805  5,703  13,396  10,098  Operating expenses        Cost of product sales808  551  1,524  1,051  Research and development8,781  22,043  17,964  43,287  Selling, general and administrative8,677  11,323  16,829  23,643  Total operating expenses18,266  33,917  36,317  67,981  Loss from operations(12,461) (28,214) (22,921) (57,883) Other income (expense)        Interest expense(2,470) (2,806) (4,876) (5,535) Interest income32  604  222  1,317  Other income—related party—  —  4,085  —  Other expense(693) —  (693) —  Total other income (expense), net(3,131) (2,202) (1,262) (4,218) Net loss$(15,592) $(30,416) $(24,183) $(62,101) Net loss per share, basic and diluted$(0.57) $(1.12) $(0.89) $(2.29) Weighted-average common shares outstanding, basic and diluted27,326  27,108  27,282  27,071               LA JOLLA PHARMACEUTICAL COMPANYCondensed Consolidated Statements of Cash Flows (Unaudited) Six Months Ended June 30,  2020 2019 Operating activities    Net loss$(24,183) $(62,101) Adjustments to reconcile net loss to net cash used for operating activities:    Share-based compensation expense3,997  13,103  Depreciation and amortization expense1,798  2,263  Loss on disposal of equipment904  15  Unrealized gains on short-term investments(63) —  Non-cash interest expense3,392  4,678  Non-cash rent expense699  639  Changes in operating assets and liabilities:    Accounts receivable, net1,117  (512) Inventory, net(909) 52  Prepaid expenses and other current assets1,675  22  Accounts payable(1,696) (3,664) Accrued expenses(3,378) 974  Accrued payroll and related expenses(2,591) (3,429) Lease liability(1,357) (1,241) Net cash used for operating activities(20,595) (49,201) Investing activities    Proceeds from the sale of property and equipment2,860  —  Purchase of property and equipment—  (441) Purchase of short-term investments(2,999) —  Net cash used for investing activities(139) (441) Financing activities    Net proceeds from issuance of common stock under 2013 Equity Plan605  —  Net proceeds from issuance of common stock under ESPP359  484  Net cash provided by financing activities964  484  Net decrease in cash and restricted cash(19,770) (49,158) Cash and restricted cash at beginning of period88,729  173,513  Cash and restricted cash at end of period$68,959  $124,355  Supplemental disclosure of non-cash investing and financing activities:    Conversion of Series F Convertible Preferred Stock into common stock$—  $2,737  Cumulative-effect adjustment from adoption of ASU 2018-07$—  $(160) Initial recognition of right-of-use lease asset$—  $16,798  Reconciliation of cash and restricted cash to the condensed consolidated balance sheets Cash$68,353  $123,446  Restricted cash606  909  Total cash and restricted cash$68,959  $124,355           La Jolla Pharmaceutical Company Contact Michael Hearne Chief Financial Officer La Jolla Pharmaceutical Company (858) 333-5769 mhearne@ljpc.com

  • Larry Edwards Appointed President and Chief Executive Officer of La Jolla Pharmaceutical Company
    on July 28, 2020 at 8:16 pm

    SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that its Board of Directors has appointed Larry Edwards as President and Chief Executive Officer. “Larry has an impressive track record bringing innovative treatments that address unmet medical needs to patients in the acute-care setting," said Kevin Tang, Chairman of La Jolla. “We are delighted to have Larry join the Company.”“I look forward to working with the La Jolla team to continue to expand patient access to GIAPREZA and XERAVA,” said Larry Edwards, President and Chief Executive Officer of La Jolla. “I am grateful to have the opportunity to join a company that focuses on improving outcomes in patients suffering from life-threatening diseases.” From 2015 to 2020, Mr. Edwards served in various positions at Tetraphase Pharmaceuticals, Inc., most recently serving as Chief Executive Officer. From 2014 to 2015, he served as Senior Director of Marketing of the Gram-negative Franchise of Cubist Pharmaceuticals, Inc. (acquired by Merck & Co., Inc.). From 1999 to 2014, Mr. Edwards served in various positions at Merck and Co., Inc., most recently serving as Global Marketing Director of Clostridium Difficile and New Infectious Disease Products. Mr. Edwards received a B.S. degree in business and healthcare administration from Ohio University.About GIAPREZAGIAPREZA™ (angiotensin II) for injection was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. GIAPREZA mimics the body’s endogenous angiotensin II peptide, which is central to the renin-angiotensin-aldosterone system, which in turn regulates blood pressure. Prescribing information for GIAPREZA is available at www.giapreza.com. The European Summary of Product Characteristics is available on the EMA website: www.ema.europa.eu/en/medicines/human/EPAR/giapreza. GIAPREZA is marketed in the U.S. by La Jolla Pharmaceutical Company on behalf of La Jolla Pharma, LLC, its wholly owned subsidiary.GIAPREZA Important Safety InformationContraindicationsNone.Warnings and PrecautionsThere is a potential for venous and arterial thrombotic and thromboembolic events in patients who receive GIAPREZA. Use concurrent venous thromboembolism (VTE) prophylaxis.Adverse ReactionsThe most common adverse reactions that were reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events.Drug InteractionsAngiotensin converting enzyme (ACE) inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers (ARBs) may reduce response to GIAPREZA.You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.For additional information, please see Full Prescribing Information for the United States and the Summary of Product Characteristics for the European Union.About XERAVAXERAVA™ (eravacycline) for injection was approved by the U.S. Food and Drug Administration (FDA) as a novel fluorocycline of the tetracycline class antibacterials indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older. XERAVA was investigated for the treatment of cIAI as part of Tetraphase's IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) Phase 3 program. In the first pivotal Phase 3 trial in patients with cIAI, twice-daily intravenous (IV) XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to ertapenem and was well tolerated. In the second Phase 3 clinical trial in patients with cIAI, twice-daily IV XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to meropenem and was well tolerated. In both trials, XERAVA achieved high cure rates in patients with Gram-negative pathogens, including resistant isolates. Prescribing information for XERAVA is available at www.xerava.com. XERAVA is marketed in the U.S. by Tetraphase Pharmaceuticals, Inc., a wholly owned subsidiary of La Jolla.XERAVA Important Safety InformationXERAVA is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older.XERAVA is not indicated for the treatment of complicated urinary tract infections.To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.XERAVA is contraindicated for use in patients with known hypersensitivity to eravacycline, tetracycline-class antibacterial drugs or to any of the excipients. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with XERAVA.The use of XERAVA during tooth development (last half of pregnancy, infancy and childhood to the age of eight years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.The use of XERAVA during the second and third trimester of pregnancy, infancy and childhood up to the age of eight years may cause reversible inhibition of bone growth.Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis.The most common adverse reactions observed in clinical trials (incidence ≥ 3%) were infusion site reactions, nausea and vomiting.XERAVA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions including photosensitivity, pseudotumor cerebri and anti-anabolic action, which has led to increased blood urea nitrogen, azotemia, acidosis, hyperphosphatemia, pancreatitis and abnormal liver function tests, have been reported for other tetracycline-class antibacterial drugs, and may occur with XERAVA. Discontinue XERAVA if any of these adverse reactions are suspected.You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.For additional information, please see Full Prescribing Information for the United States.About La Jolla Pharmaceutical CompanyLa Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZA™ (angiotensin II) is approved by the U.S. FDA as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock.  XERAVA™ (eravacycline), is approved by the U.S. FDA for the treatment of complicated intra-abdominal infections. For more information, please visit www.ljpc.com.Forward-looking StatementsThis press release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: GIAPREZA™ (angiotensin II) and XERAVATM (eravacycline) sales; whether La Jolla will realize the benefits from the acquisition of Tetraphase Pharmaceuticals, Inc.; regulatory actions relating to La Jolla’s products by the U.S. FDA, European Commission and/or other regulatory authorities; cash used in operating activities and our capital requirements; and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.La Jolla Pharmaceutical Company Contact:Michael Hearne Chief Financial Officer La Jolla Pharmaceutical Company (858) 333-5769 mhearne@ljpc.com

  • La Jolla Pharmaceutical Company Announces the Closing of Acquisition of Tetraphase Pharmaceuticals, Inc.
    on July 28, 2020 at 8:15 pm

    -Combined Company Offers Two Innovative Therapies to Treat Patients Suffering from Life-threatening Diseases-SAN DIEGO, California and WATERTOWN, Massachusetts, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, and Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline) to treat serious and life-threatening infections, today announced the closing of La Jolla's acquisition of Tetraphase. La Jolla acquired Tetraphase for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights (CVRs). The holders of the CVRs are entitled to receive payments of up to an additional $16.0 million in the aggregate upon the achievement of certain net sales of XERAVA in the United States. “With two, FDA-approved, innovative therapies for life-threatening diseases, La Jolla is well-positioned to help patients in need,” said Larry Edwards, President and Chief Executive Officer of La Jolla. “By leveraging the stronger platform that the combined company will provide, we look forward to increasing patient access to these important medicines.”About GIAPREZAGIAPREZA™ (angiotensin II) for injection was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. GIAPREZA mimics the body’s endogenous angiotensin II peptide, which is central to the renin-angiotensin-aldosterone system, which in turn regulates blood pressure. Prescribing information for GIAPREZA is available at www.giapreza.com. The European Summary of Product Characteristics is available on the EMA website: www.ema.europa.eu/en/medicines/human/EPAR/giapreza. GIAPREZA is marketed in the U.S. by La Jolla Pharmaceutical Company on behalf of La Jolla Pharma, LLC, its wholly owned subsidiary.GIAPREZA Important Safety InformationContraindicationsNone.Warnings and PrecautionsThere is a potential for venous and arterial thrombotic and thromboembolic events in patients who receive GIAPREZA. Use concurrent venous thromboembolism (VTE) prophylaxis.Adverse ReactionsThe most common adverse reactions that were reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events.Drug InteractionsAngiotensin converting enzyme (ACE) inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers (ARBs) may reduce response to GIAPREZA.You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.For additional information, please see Full Prescribing Information for the United States and the Summary of Product Characteristics for the European Union.About XERAVAXERAVA™ (eravacycline) for injection was approved by the U.S. Food and Drug Administration (FDA) as a novel fluorocycline of the tetracycline class antibacterials indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older. XERAVA was investigated for the treatment of cIAI as part of Tetraphase's IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) Phase 3 program. In the first pivotal Phase 3 trial in patients with cIAI, twice-daily intravenous (IV) XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to ertapenem and was well tolerated. In the second Phase 3 clinical trial in patients with cIAI, twice-daily IV XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to meropenem and was well tolerated. In both trials, XERAVA achieved high cure rates in patients with Gram-negative pathogens, including resistant isolates. Prescribing information for XERAVA is available at www.xerava.com. XERAVA is marketed in the U.S. by Tetraphase Pharmaceuticals, Inc., a wholly owned subsidiary of La Jolla.XERAVA Important Safety InformationXERAVA is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older.XERAVA is not indicated for the treatment of complicated urinary tract infections.To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.XERAVA is contraindicated for use in patients with known hypersensitivity to eravacycline, tetracycline-class antibacterial drugs or to any of the excipients. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with XERAVA.The use of XERAVA during tooth development (last half of pregnancy, infancy and childhood to the age of eight years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.The use of XERAVA during the second and third trimester of pregnancy, infancy and childhood up to the age of eight years may cause reversible inhibition of bone growth.Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis.The most common adverse reactions observed in clinical trials (incidence ≥ 3%) were infusion site reactions, nausea and vomiting.XERAVA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions including photosensitivity, pseudotumor cerebri and anti-anabolic action, which has led to increased blood urea nitrogen, azotemia, acidosis, hyperphosphatemia, pancreatitis and abnormal liver function tests, have been reported for other tetracycline-class antibacterial drugs, and may occur with XERAVA. Discontinue XERAVA if any of these adverse reactions are suspected.You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.For additional information, please see Full Prescribing Information for the United States.About La Jolla Pharmaceutical CompanyLa Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZA™ (angiotensin II) is approved by the U.S. FDA as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock.  XERAVA™ (eravacycline) is approved by the U.S. FDA for the treatment of complicated intra-abdominal infections. For more information, please visit www.ljpc.com.Forward-looking StatementsThis press release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: GIAPREZA™ (angiotensin II) and XERAVA™ (eravacycline) sales; whether La Jolla will realize the benefits from the acquisition of Tetraphase Pharmaceuticals, Inc.; regulatory actions relating to La Jolla’s products by the U.S. FDA, European Commission and/or other regulatory authorities; cash used in operating activities and our capital requirements; and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.La Jolla Pharmaceutical Company Contact: Michael Hearne Chief Financial Officer La Jolla Pharmaceutical Company (858) 333-5769 mhearne@ljpc.com

  • La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.
    on June 24, 2020 at 11:30 am

    La Jolla Pharmaceutical Company (LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, and Tetraphase Pharmaceuticals, Inc. (TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ to treat serious and life-threatening infections, today announced that they have entered into a definitive merger agreement. Under the terms of the definitive merger agreement, La Jolla would acquire Tetraphase, through a tender offer, for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights (CVRs).

  • La Jolla Pharmaceutical Rekindles Interest In Tetraphase With Sweetened Offer
    on June 22, 2020 at 4:14 pm

    The bidding war for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) seems to be far from over.What Happened: Tetraphase announced Monday that La Jolla Pharmaceutical Company (NASDAQ: LJPC) has approached the company with an unsolicited acquisition proposal for $43 million in cash, plus an additional aggregate amount of $16 million in cash, potentially payable under contingent value rights issued in the transaction.Tetraphase markets Xerava, an antibiotic for treating complicated intra-abdominal infections. After Tetraphase signed an agreement to be acquired by AcelRx Pharmaceuticals Inc (NASDAQ: ACRX), La Jolla jumped into the fray in early May, with an offer amounting to $22 million in cash and $12.5 million in CVRs.Subsequently, privately held Melinta Therapeutics also joined the race, and surprisingly La Jolla stayed away.After AcelRx and Melinta fought it out with bids and counter-bids, Tetraphase terminated its agreement with AcelRx June 4,and executed a merger agreement with Melinta, which had offered $43 million in cash and $16 million in CVRs.Even as the bidding war seemed to have ended, La Jolla has re-entered the fray.What's Next: With Tetraphase's board deeming La Jolla's offer a superior one, the company said it has given notice to Melinta regarding its intention to change its recommendation unless Melinta revises its offer on or before June 26.TTPH, LJPC Price Action: At last check, Tetraphase shares were adding 1.52% to $2.67, while La Jolla was slipping 3.77% to $5.11. Related Links:The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions Novavax Beefs Up Executive Team As It Sprints In The Coronavirus Vaccine Race See more from Benzinga * The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset * The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic * The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To 0M In Biotechs(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Is La Jolla Pharmaceutical Company (LJPC) Going to Burn These Hedge Funds?
    on June 10, 2020 at 8:22 pm

    Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out

  • How La Jolla (LJPC) Stock Stands Out in a Strong Industry
    on May 21, 2020 at 12:30 pm

    La Jolla (LJPC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  • Bidding War Sends Tetraphase Shares Soaring
    on May 7, 2020 at 4:55 pm

    Shares of nano-cap Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH), which have never really recovered from a steep sell-off triggered by an adverse clinical readout in late 2015, are surging Thursday after a second bidder emerged.Two-way Race The Watertown, Massachusetts-based company, which has a commercial antibiotic called Xerava to treat serious and life-threatening infections, is being pursued by La Jolla Pharmaceutical Company (NASDAQ: LJPC) after it signed a definitive agreement to be acquired by AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) in mid-March.La Jolla revealed in a filing it submitted a non-binding offer to acquire 100% of the equity of Tetraphase in an all-cash transaction.La Jolla offered for Tetraphase $22 million in cash, plus an additional $12.5 million potentially payable under contingent value rights, or CVRs, to be issued in the transaction.A contingent value right is a derivative instrument, with its value depending on some future event. If the event occurs by the specified date, then a holder of the CVR will get a pre-determined payout, mostly in cash."We are impressed with the growth potential of XERAVA and excited about the potential benefits of combining two companies focused on delivering important therapies to patients in the ICU," said Kevin Tang, Chairman of La Jolla in a letter addressed to the board of Tetraphase.Xerava, which was approved in August 2018, fetched Tetraphase revenues of $3.6 million in 2019 and $1.46 million in the fourth quarter of 2019.La Jolla said it plans to finance the proposed transaction with its cash on hand.Related Link: Attention Biotech Investors: Mark Your Calendar For These May PDUFA DatesAbout three weeks back, Tetraphase announced a definitive merger with AcelRx in a stock-for-stock transaction. The agreement provided for Tetraphase shareholders receiving 0.6303 share of AcelRx stock for each share they hold in Tetraphase, and a CVR, which will give the holders the right to receive aggregate payments of up to $12.5 million on achievement of future Xerava net sales milestones starting in 2021.The stock exchange ratio suggested valuation of $14.4 million at the close of trading March 13, a day before the deal was made public.AcelRx had said then it expects the deal to close in the second quarter. The boards of both companies vetted the transaction and certain stock and warrant holders holding an aggregate of approximately 31% of Tetraphase stock voting in favor of the deal.Merits Of The Offers La Jolla's superior cash offer cash might seem attractive at this juncture, as the world navigates through one of the worst crises it has ever faced."In our view, La Jolla's offer to Tetraphase hinges on an approximate $2.0M up-front premium to AcelRx's offer," H.C. Wainwright analyst Ed Arce said in a note. Despite La Jolla's higher consideration, he said Tetraphase might stick with the AcelRx offer.The terms of CVRs offered by both companies are same, except that La Jolla's CVRs would be paid in cash instead of cash or stock at the acquirer's option."We do not believe La Jolla's unsolicited competing bid is sufficiently compelling to Tetraphase to pull the company away from the current proposed transaction, especially given the amount of commitment and pre-close integration with AcelRx to date," Arce wrote in the note.The TTPH Move Tetraphase was up 89% to $2.63 at time of publication.Latest Ratings for TTPH DateFirmActionFromTo Mar 2020Gabelli & Co.DowngradesHoldSell Jan 2020Gabelli & Co.DowngradesBuyHold Oct 2019Gabelli & Co.UpgradesHoldBuy View More Analyst Ratings for TTPH View the Latest Analyst Ratings See more from Benzinga * The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test * The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

FULL NAME*

What's Your Role?*

WORK EMAIL*

COMPANY NAME*

Company Description*

HOW'D YOU HEAR ABOUT US?

DETAILS ABOUT YOUR GOALS

La Jolla Pharmaceutical Company

10182 Telesis Court
6th Floor
San Diego, CA 92121

+1 (858) 207-4264

www.lajollapharmaceutical.com

September 2020
S M T W T F S
 12345
6789101112
13141516171819
20212223242526
27282930  

©2020 ALIGNMT LLC | Alignment Strategy | Mergers & Acquisitions | Investor Relations

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account